Market Cap 1.12B
Revenue (ttm) 23.68M
Net Income (ttm) -318.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,346.11%
Debt to Equity Ratio 1.19
Volume 1,149,700
Avg Vol 2,184,042
Day's Range N/A - N/A
Shares Out 86.02M
Stochastic %K 14%
Beta 1.28
Analysts Strong Sell
Price Target $36.78

Latest News on SNDX

Syndax Announces Participation in March Investor Conferences

Feb 25, 2025, 7:00 AM EST - 5 weeks ago

Syndax Announces Participation in March Investor Conferences


Syndax Announces Participation in February Investor Conferences

Jan 30, 2025, 7:00 AM EST - 2 months ago

Syndax Announces Participation in February Investor Conferences


US FDA approves Syndax's blood cancer drug

Nov 15, 2024, 6:26 PM EST - 4 months ago

US FDA approves Syndax's blood cancer drug


Syndax Announces Participation in November Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 5 months ago

Syndax Announces Participation in November Investor Conferences


FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks

Jul 29, 2024, 2:51 PM EDT - 8 months ago

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks


Under-the-radar biotech bets

Apr 3, 2024, 1:47 PM EDT - 1 year ago

Under-the-radar biotech bets

CRNX MRUS XBI